Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Head of R&D & Chief Medical Officer Ran Meir - SVP, head of IR Conference Call Participants Umer Raffat - Evercore ISI Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Chris Schott - J.P. Morgan Ash Verma - UBS Yifeng Liu - HSBC Operator Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited Earnings Conference Call.
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teva Pharm CEO says will work productively with Trump administration
Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, chief executive Richard Francis said on Wednesday.
Teva Pharmaceutical third-quarter profit, revenue top estimates
Teva Pharmaceutical Industries reported a larger than expected rise in third-quarter profit, boosted by strong sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease.
Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?
Teva Pharmaceutical Industries (TEVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Teva fined $503 mln by EU for disparaging rival product
The European Commission has fined Teva , the world's largest generic drugmaker, 462.6 million euros ($503 million) for abusing its dominant position to delay competition to its blockbuster multiple sclerosis medicine Copaxone, confirming a Reuters exclusive.
Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.1% in Teva Pharmaceutical Industries (TEVA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing drugs on the market across multiple clinical segments, including cancer drugs. Debt to equity is high vs peers; however, debt is on a declining trend.
Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says
New Jersey-based drugmaker Teva has agreed to pay $450 million to resolve allegations that it violated an anti-kickback statute and the False Claims Act, the U.S. Justice department said in a statement on Thursday.
